{"entity":{"id":"nct04098744","kind":"trial","name":"Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)","aka":[],"tldr":"A phase 2 trial of Artesunate vaginal insert in vaginal cancer, run by Frantz Viral Therapeutics, LLC, now recruiting.","summary":"Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) is a phase 2 interventional study registered as NCT04098744 by Frantz Viral Therapeutics, LLC, with 78 participants planned, started 2020-09-09 and due to reach its primary completion in 2026-07-31. Interventions recorded: Artesunate vaginal insert and Placebo vaginal insert.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04098744","url":"https://clinicaltrials.gov/study/NCT04098744"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["vaginal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04098744","phase":"2","setting":"A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2/3)","sponsor":"Frantz Viral Therapeutics, LLC","enrolled":78,"outcomes":[]},"route":"/trials/nct04098744/","neighbours":{"cancer":[{"id":"vaginal","kind":"cancer","name":"Vaginal cancer","route":"/cancers/vaginal/"}]}}